Insulin therapy in type 2 diabetes.

[1]  Philippe Lehert,et al.  Combination of insulin and metformin in the treatment of type 2 diabetes. , 2002, Diabetes care.

[2]  J. Buse,et al.  Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy , 2002 .

[3]  P. Cryer,et al.  Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes* , 2002, Diabetologia.

[4]  J. Leahy.  Intensive Insulin Therapy in Type 1 Diabetes Mellitus , 2002 .

[5]  M Peyrot,et al.  Psychological issues and treatments for people with diabetes. , 2001, Journal of clinical psychology.

[6]  J. Rosenstock,et al.  Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. , 2001, Diabetes care.

[7]  D. Nathan.  Inhaled Insulin for Type 2 Diabetes: Solution or Distraction? , 2001, Annals of Internal Medicine.

[8]  W. Cefalu,et al.  Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.

[9]  K. Hermansen,et al.  Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. , 2001, Diabetes care.

[10]  S. Mudaliar,et al.  New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. , 2001, Annual review of medicine.

[11]  G. Eisenbarth,et al.  MICA polymorphism is associated with type 1 diabetes in the Korean population. , 2001, Diabetes care.

[12]  P. Brunetti,et al.  Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. , 2000, Diabetes.

[13]  D. Laight.  Therapeutic approaches to insulin resistance , 2000 .

[14]  A. Lindholm,et al.  Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[15]  P. Raskin,et al.  A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. , 2000, Diabetes care.

[16]  S. Schwartz,et al.  Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. , 2000, Diabetes care.

[17]  J. Rosenstock,et al.  Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. , 2000, Diabetes care.

[18]  A. Riis,et al.  Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart , 2000, European Journal of Clinical Pharmacology.

[19]  H. Yki-Järvinen,et al.  Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. , 2000, Diabetes care.

[20]  A. Zinsmeister,et al.  Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[21]  M. Johannesson,et al.  Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. , 2000, European heart journal.

[22]  L Heinemann,et al.  Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. , 2000, Diabetes care.

[23]  I. Hirsch,et al.  Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. , 2000, Diabetes care.

[24]  M. Shichiri,et al.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. , 2000, Diabetes care.

[25]  T. Pieber,et al.  Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. , 2000, Diabetes care.

[26]  B. Campaigne,et al.  Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. , 2000, Clinical therapeutics.

[27]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[28]  J. Olefsky,et al.  A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. , 1999, Diabetes.

[29]  C. Bogardus,et al.  The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.

[30]  P. Raskin,et al.  Effects of Metformin in Patients with Poorly Controlled, Insulin-Treated Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[31]  P. Roach,et al.  Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. , 1999, Diabetes care.

[32]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[33]  L. Ryysy,et al.  Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[34]  Melvin Prince,et al.  The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. , 1999, Diabetes care.

[35]  D. Bruttomesso,et al.  Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. , 1999, Diabetes.

[36]  F. Nuttall,et al.  Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. , 1998, Archives of internal medicine.

[37]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[38]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[39]  J. Buse,et al.  Troglitazone Use in Insulin-Treated Type 2 Diabetic Patients , 1998, Diabetes Care.

[40]  M. Riddle,et al.  Beginning Insulin Treatment of Obese Patients With Evening 70/30 Insulin Plus Glimepiride Versus Insulin Alone , 1998, Diabetes Care.

[41]  O. Kolterman,et al.  Pramlintide, a Synthetic Analog of Human Amylin, Improves the Metabolic Profile of Patients With Type 2 Diabetes Using Insulin , 1998, Diabetes Care.

[42]  F. Nuttall,et al.  Response to Intensive Therapy Steps and to Glipizide Dose in Combination With Insulin in Type 2 Diabetes: VA feasibility study on glycemic control and complications (VA CSDM) , 1998, Diabetes Care.

[43]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[44]  P. Raskin,et al.  Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. , 1998, The New England journal of medicine.

[45]  L. Niskanen,et al.  Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. , 1997, Journal of Clinical Endocrinology and Metabolism.

[46]  F. Holleman,et al.  Reduced Frequency of Severe Hypoglycemia and Coma in Well-Controlled IDDM Patients Treated With Insulin Lispro , 1997, Diabetes Care.

[47]  W. Manning,et al.  Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. , 1997, JAMA.

[48]  J. Colwell.  Controlling type 2 diabetes: are the benefits worth the costs? , 1997, JAMA.

[49]  L. Vignati,et al.  Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. , 1997, Archives of internal medicine.

[50]  K. Malmberg.  Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.

[51]  F. Nuttall,et al.  Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. , 1997, Archives of internal medicine.

[52]  R. Henry,et al.  Diagnosis and Management of Type 2 Diabetes , 1997 .

[53]  R. Klein,et al.  Evaluations of Retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): A feasibility study , 1996, Diabetes Care.

[54]  R. Henry,et al.  Acute Effects of Intraperitoneal Versus Subcutaneous Insulin Delivery on Glucose Homeostasis in Patients With NIDDM , 1996, Diabetes Care.

[55]  A. Giobbie-Hurder,et al.  Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. , 1996, JAMA.

[56]  U. Kabadi,et al.  Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. , 1996, Archives of internal medicine.

[57]  L. Rossetti.  Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. , 1995, Clinical and investigative medicine. Medecine clinique et experimentale.

[58]  G. Slama,et al.  Multicentre Trial of a Programmable Implantable Insulin Pump in Type I Diabetes , 1995, The International journal of artificial organs.

[59]  R. DeFronzo,et al.  Bedtime Insulin/Daytime Glipizide: Effective Therapy for Sulfonylurea Failures in NIDDM , 1995, Diabetes.

[60]  S. Ross,et al.  The Efficacy of Acarbose in the Treatment of Patients with NonInsulin-Dependent Diabetes Mellitus: A Multicenter, Controlled Clinical Trial , 1994, Annals of Internal Medicine.

[61]  P. Reichard,et al.  Mortality and Treatment Side-Effects During Long-Term Intensified Conventional Insulin Treatment in the Stockholm Diabetes Intervention Study , 1994, Diabetes.

[62]  J. A. Hunt,et al.  The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus , 1994 .

[63]  V. Koivisto.  Insulin Therapy in Type II Diabetes , 1993, Diabetes Care.

[64]  Pi-Sunyer Fx.  Short-Term Medical Benefits and Adverse Effects of Weight Loss , 1993 .

[65]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[66]  L. Groop,et al.  Antibodies to Glutamic Acid Decarboxylase Reveal Latent Autoimmune Diabetes Mellitus in Adults With a Non—Insulin-Dependent Onset of Disease , 1993, Diabetes.

[67]  R. Henry,et al.  Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial , 1993, Diabetes Care.

[68]  F. Pi‐Sunyer,et al.  Medical Hazards of Obesity , 1993, Annals of Internal Medicine.

[69]  K. T. Chen,et al.  Epidemiology of Diabetes Mellitus , 1992 .

[70]  L. Niskanen,et al.  Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. , 1992, The New England journal of medicine.

[71]  P. Raskin.  Combination therapy in NIDDM. , 1992, The New England journal of medicine.

[72]  D. Owens,et al.  Relationship Between Absorption of Radiolabeled Soluble Insulin, Subcutaneous Blood Flow, and Anthropometry , 1992, Diabetes Care.

[73]  R. DeFronzo.  Insulin Resistance, Hyperinsulinemia, and Coronary Artery Disease: A Complex Metabolic Web , 1992, Journal of cardiovascular pharmacology.

[74]  G. Schernthaner,et al.  The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study. , 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[75]  J. Pugh,et al.  Is Combination Sulfonylurea and Insulin Therapy Useful in NIDDM Patients?: A metaanalysis , 1992, Diabetes Care.

[76]  L. Groop,et al.  Morning or Bedtime NPH Insulin Combined With Sulfonylurea in Treatment of NIDDM , 1992, Diabetes Care.

[77]  A. Greco,et al.  The Beta Cell Function in NIDDM Patients with Secondary Failure: , 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[78]  W. Duckworth,et al.  Why Intraperitoneal Delivery of Insulin With Implantable Pumps in NIDDM? , 1992, Diabetes.

[79]  W. Duckworth,et al.  The Department of Veterans Affairs Implanted Insulin Pump Study , 1992, Diabetes Care.

[80]  M. Riddle,et al.  Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. , 1992, The American journal of the medical sciences.

[81]  R. DeFronzo,et al.  Pathogenesis of NIDDM: A Balanced Overview , 1992, Diabetes Care.

[82]  S. Heshka,et al.  Combination Therapy for NIDDM With Biosynthetic Human Insulin and Glyburide , 1992, Diabetes Care.

[83]  S. Efendić,et al.  Effects of Combination Therapy With Glyburide and Insulin on Serum Lipid Levels in NIDDM Patients With Secondary Sulfonylurea Failure , 1991, Diabetes Care.

[84]  J. Caro.  Clinical review 26: Insulin resistance in obese and nonobese man. , 1991, The Journal of clinical endocrinology and metabolism.

[85]  J. Talbot,et al.  Randomized Trial Comparing Continuous Subcutaneous Insulin Infusion and Conventional Insulin Therapy in Type II Diabetic Patients Poorly Controlled With Sulfonylureas , 1991, Diabetes Care.

[86]  R. Vigneri,et al.  Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide. , 1991, Diabete & metabolisme.

[87]  J. Galloway.  Treatment of NIDDM With Insulin Agonists or Substitutes , 1990, Diabetes Care.

[88]  S. Genuth.  Insulin Use in NIDDM , 1990, Diabetes Care.

[89]  R. Holman,et al.  Insulin Use in NIDDM: Rationale Based on Pathophysiology of Disease , 1990, Diabetes Care.

[90]  M. Riddle.  Evening Insulin Strategy , 1990, Diabetes Care.

[91]  T. Bailey,et al.  Combination Therapy With Insulin and Sulfonylureas for Type II Diabetes , 1990, Diabetes Care.

[92]  H. Lebovitz,et al.  Combination Insulin-Sulfonylurea Therapy , 1990, Diabetes Care.

[93]  M. Funnell,et al.  Feasibility of Adjustment of Insulin Dose by Insulin-Requiring Type II Diabetic Patients , 1990, Diabetes Care.

[94]  M. Taskinen,et al.  Bedtime Insulin for Suppression of Overnight Free–Fatty Acid, Blood Glucose, and Glucose Production in NIDDM , 1989, Diabetes.

[95]  M. Davidson.  Futility of Self-Monitoring of Blood Glucose Without Algorithms for Adjusting Insulin Doses , 1986, Diabetes Care.

[96]  G. Bray,et al.  Management of Obesity by Severe Caloric Restriction , 1985 .

[97]  R. Hamman,et al.  The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus , 1985, Diabetes.

[98]  W. J. Andrews,et al.  Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal , 1984, Diabetes.

[99]  K. Polonsky,et al.  C-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations , 1984, Diabetes.

[100]  J. A. Scarlett,et al.  Insulin Treatment Reverses the Insulin Resistance of Type II Diabetes Mellitus , 1982, Diabetes Care.

[101]  L. Mandarino,et al.  Dose-response characteristics for effects of insulin on production and utilization of glucose in man. , 1981, The American journal of physiology.

[102]  D L McGee,et al.  Diabetes and Cardiovascular Risk Factors: The Framingham Study , 1979, Circulation.

[103]  R. DeFronzo,et al.  Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. , 1978, The Journal of clinical investigation.

[104]  E. Joslin,et al.  Joslin's Diabetes Mellitus , 1971 .

[105]  R. Cecil.  Textbook of Medicine , 1927 .